CABA: Cabaletta Bio 10-Q reports no product revenue and needs more funding
Q3 2026 10-Q: no product revenue; mentions $93.6M net proceeds from prior offering and need for substantial additional funding.
What this filing says
Cabaletta Bio filed its quarterly report for the period ended September 30, 2026. The filing says the company has not generated product revenue and does not expect to for several years, if at all, and that it will need to raise substantial additional funding before completing development of its product candidates. For a shareholder, this points to continued cash needs that could lead to further share issuance.
Key figures
- Shares outstanding
- 215,720,392 shares
- Aggregate net offering proceeds
- $93,558 thousand
- Common stock warrant exercise price
- $2.50
- Combined offering price per share and warrant
- $2.00
Positive for shareholders
- Rese-cel has received several FDA and EMA regulatory designations intended to speed clinical development.
Negative for shareholders
- The company has not generated product revenue and does not expect product sales for several years, if at all.
- Substantial additional funding will be needed before development of its product candidates can be completed.
- A recent offering sold shares alongside warrants, which could dilute existing holders if exercised.
Written by Quantisnow AI from this filing. Not financial advice.
Key terms
- Pre-funded warrant:
- A warrant sold with a nominal exercise price that lets the holder buy common stock later, usually used when buyers would exceed an ownership limit.
- Regenerative Medicine Advanced Therapy (RMAT) designation:
- An FDA designation for serious conditions that can speed development and review of cell or gene therapies.
- Orphan Drug designation:
- An FDA status for drugs treating rare diseases that can bring development incentives such as tax credits and market exclusivity.
FAQ
Has Cabaletta Bio generated revenue from product sales?
No. The filing says the company has not generated any revenue from product sales and does not expect to for several years, if at all.
Does Cabaletta Bio need more money?
Yes. The filing states the company will need to raise substantial additional funding before it can expect to complete development of any product candidates or generate product revenue.
Historical context for CABA
Across the 17 sessions after earlier CABA headlines, the stock closed higher 7 times and lower 10 times, with a median move of 4.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CABA | SPY |
|---|---|---|---|
| Nov 5, 2026 | Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Updateand 1 other headline that session | -9.9% | -4.4% |
| Nov 3, 2026 | Cabaletta Bio to Participate in Upcoming Investor Conferences | -0.7% | +0.3% |
| Oct 6, 2026 | Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -2.9% | +0.5% |
| Sep 1, 2026 | Cabaletta Bio to Participate in Upcoming Investor Conferences | +6.1% | -0.7% |
| Aug 13, 2026 | Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update | -4.9% | +0.7% |
| Jun 3, 2026 | Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress | -2.7% | -0.7% |
Keep researching CABA
- CABA financial statementsRevenue, profit, cash flow and balance sheet from Cabaletta Bio Inc.'s SEC filings.
- What is Form 10-Q?The quarterly report US public companies file with the SEC for each of the first three fiscal quarters, with unaudited financial statements and MD&A.
- Form 10-K vs 10-QThe difference between a 10-K and a 10-Q: what each report contains, filing deadlines by company size, audited vs reviewed financials, and which sections to read first.
- CABA insider tradesEvery buy and sale reported by Cabaletta Bio Inc. officers, directors and large holders.
- CABA earnings historyPast Cabaletta Bio Inc. earnings releases, newest first.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2019
Follow CABA and get a push notification the moment its next story breaks.